AI Verdict
PBYI has stronger fundamentals based on our AI analysis.
PCRX vs PBYI Fundamental Comparison
| Metric | PCRX | PBYI |
|---|---|---|
| Revenue | $726.4M | $228.4M |
| Net Income | $7.0M | $31.1M |
| Net Margin | 1.0% | 13.6% |
| ROE | 1.0% | 23.9% |
| ROA | 0.6% | 14.4% |
| Current Ratio | 4.54x | 2.00x |
| Debt/Equity | 0.54x | 0.17x |
| EPS | $0.16 | $0.61 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PCRX vs PBYI: Frequently Asked Questions
Is PCRX or PBYI a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), PBYI has stronger fundamentals. PCRX is rated HOLD (65% confidence) while PBYI is rated BUY (72% confidence). This is not investment advice.
How does PCRX compare to PBYI fundamentally?
Pacira BioSciences, Inc. has ROE of 1.0% vs PUMA BIOTECHNOLOGY, INC.'s 23.9%. Net margins are 1.0% vs 13.6% respectively.
Which stock pays higher dividends, PCRX or PBYI?
PCRX has a dividend yield of N/A or no dividend while PBYI has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PCRX or PBYI for long term?
For long-term investing, consider that PCRX has HOLD rating with 65% confidence, while PBYI has BUY rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PCRX vs PBYI?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PCRX vs PBYI, the AI consensus favors PBYI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.